Fut, nem toboroz
Study of an On-Body Injection System for Home Use of Ocrelizumab in People with Multiple Sclerosis
2025-523726-40-00· 3. fázis· F. Hoffmann-La Roche AG· Forrás
Toboroz
A Study to Evaluate Pharmacokinetics (PK) and Safety of Subcutaneous (SC) Ublituximab Administered at Various Injection Sites and Relative Bioavailability Via Autoinjector (AI) Versus Syringe Subcutaneously in Participants With Multiple Sclerosis (MS)
NCT07503873· 2. fázis· TG Therapeutics, Inc.· Forrás
Toboroz
A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis
NCT07299019· 3. fázis· Zenas BioPharma (USA), LLC· Forrás
Toboroz
Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis
NCT07325292· 3. fázis· Sanofi· Forrás
Fut, nem toboroz
A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS)
NCT07074886· 2. fázis· Hoffmann-La Roche· Forrás
Toboroz
A Randomized, Double-blind, Study to Demonstrate Pharmacokinetic Similarity, and Evaluate Safety, Immunogenicity, Pharmacodynamics and Clinical Effects between ABP 692 and Ocrevus® (Ocrelizumab) in Subjects with Relapsing-remitting Multiple Sclerosis
2024-512914-16-00· 3. fázis· Amgen Inc.· Forrás
Toboroz
A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)
2024-517529-26-00· 3. fázis· Dianthus Therapeutics Inc.· Forrás
Fut, nem toboroz
Comparative PK, PD, Efficacy, and Safety Assessment of the Proposed Ocrelizumab Biosimilar CYB704 and Ocrevus in Participants With Relapsing Multiple Sclerosis
NCT06847724· 3. fázis· Sandoz· Forrás
Fut, nem toboroz
Evaluation of intravenous or subcutaneous administration of ublituximab in patients with autoimmune diseases
2023-509555-13-00· 1. fázis· Tg Therapeutics Inc.· Forrás
Fut, nem toboroz
A Double-blind, Randomized, Active-controlled, Parallel-group, Phase 1/3 study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients with Relapsing-remitting Multiple Sclerosis.
2022-501622-37-00· 3. fázis· Celltrion Inc.· Forrás
Fut, nem toboroz
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
NCT06141473· 3. fázis· Sanofi· Forrás
Toboroz
Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab
NCT05877963· 3. fázis· TG Therapeutics, Inc.· Forrás
Fut, nem toboroz
A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis
NCT05269004· 3. fázis· Hoffmann-La Roche· Forrás
Fut, nem toboroz
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-1)
NCT05147220· 3. fázis· Novartis Pharmaceuticals· Forrás
Fut, nem toboroz
Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)
NCT04586023· 3. fázis· Hoffmann-La Roche· Forrás
Fut, nem toboroz
A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)
NCT04586010· 3. fázis· Hoffmann-La Roche· Forrás
Fut, nem toboroz
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)
NCT04548999· 3. fázis· Hoffmann-La Roche· Forrás
Fut, nem toboroz
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)
NCT04544436· 3. fázis· Hoffmann-La Roche· Forrás
Fut, nem toboroz
A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis
NCT04544449· 3. fázis· Hoffmann-La Roche· Forrás
Fut, nem toboroz
A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves)
NCT04280718· 2. fázis· argenx· Forrás
Fut, nem toboroz
An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis
NCT04130997· 3. fázis· TG Therapeutics, Inc.· Forrás
Fut, nem toboroz
A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis
NCT04035005· 3. fázis· Hoffmann-La Roche· Forrás
Fut, nem toboroz
An open-label extension study evaluating long-term safety, tolerability and effectiveness of ofatumumab in subjects with RMS
2023-507906-15-00· 3. fázis· Novartis Pharma AG· Forrás